Skip to main content

Inspire Medical Systems, Inc. (INSP) Stock Analysis

Recovery setup

SellVALUE-TRAP 1/5Moderate Confidence

Healthcare · Medical Devices

Earnings in 4 days (2026-05-04). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Momentum 3.1/10 is below the 5.0 floor at $54.49 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: Inspire system; Cyclical risk: PE expanding 1.9x (earnings normalizing).

Inspire Medical Systems is a medical technology company that develops and commercializes the Inspire neurostimulation system, the first FDA-approved implantable closed-loop device for moderate-to-severe obstructive sleep apnea, with over 125,000 patients treated. Revenue comes... Read more

$54.49+15.4% A.UpsideScore 5.8/10#5 of 40 Medical Devices
Stop $50.68Target $62.86(analyst − 13%)A.R:R 1.6:1
Analyst target$72.25+32.6%12 analysts
$62.86our TP
$54.49price
$72.25mean
$120

Sell if holding. Momentum 3.1/10 is below the 5.0 floor at $54.49 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: Inspire system; Cyclical risk: PE expanding 1.9x (earnings normalizing). Chart setup: Death cross but MACD improving, RSI 51. Score 5.8/10, moderate confidence.

Passes 5/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 4d<=7d. Suitability: aggressive.

Val7.2Qual6.0Grw5.5Mom3.1Sent6.8Ins5.1Peer6.9Tech4.2Risk4.25.8OVERALL

Thesis

Rewards
Strong earnings beat streak (4/4)
Attractive valuation
Risks
Concentration risk — Product: Inspire system
Cyclical risk: PE expanding 1.9x (earnings normalizing)
Leverage penalty (D/E 4.1): -1.5

Key Metrics

P/E (TTM)10.9
P/E (Fwd)20.7
Mkt Cap$1.5B
EV/EBITDA19.3
Profit Mgn15.9%
ROE19.8%
Rev Growth12.2%
Beta0.86
DividendNone
Rating analysts25

Quality Signals

Piotroski F7/9

Options Flow

P/C0.56bullish
IV122%elevated
Max Pain$30-44.9% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHProductInspire system
    10-K Item 1A: 'our dependency on our Inspire system for revenues'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Volume
0.0
Obv
1.0
Ma Position
1.0
Rsi
4.5
Macd
9.1
Volume distribution (falling OBV)Below 200-MA, MA slope -12.3%/30d — confirmed downtrend
GatesMomentum 3.1<4.5Death cross (50MA < 200MA)EARNINGS PROXIMITY 4d<=7dA.R:R 1.6 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARRecoverySuitability: Aggressive
RSI
51 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $51.28Resistance $58.98

Price Targets

$51
$63
A.Upside+15.4%
A.R:R1.6:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeCautious

Risk Alerts

! Momentum score 3.1/10 — below 4.5 minimum
! Death cross — 50-day MA below 200-day MA
! EARNINGS_PROXIMITY:4d<=7d

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-05-04 (4d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is INSP stock a buy right now?

Sell if holding. Momentum 3.1/10 is below the 5.0 floor at $54.49 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: Inspire system; Cyclical risk: PE expanding 1.9x (earnings normalizing). Chart setup: Death cross but MACD improving, RSI 51. Prior stop was $50.68. Score 5.8/10, moderate confidence.

What is the INSP stock price target?

Take-profit target: $62.86 (+15.4% upside). Prior stop was $50.68. Stop-loss: $50.68.

What are the risks of investing in INSP?

Concentration risk — Product: Inspire system; Cyclical risk: PE expanding 1.9x (earnings normalizing); Leverage penalty (D/E 4.1): -1.5.

Is INSP overvalued or undervalued?

Inspire Medical Systems, Inc. trades at a P/E of 10.9 (forward 20.7). TrendMatrix value score: 7.2/10. Verdict: Sell.

What do analysts say about INSP?

25 analysts cover INSP with a consensus score of 3.6/5. Average price target: $72.

What does Inspire Medical Systems, Inc. do?Inspire Medical Systems is a medical technology company that develops and commercializes the Inspire neurostimulation...

Inspire Medical Systems is a medical technology company that develops and commercializes the Inspire neurostimulation system, the first FDA-approved implantable closed-loop device for moderate-to-severe obstructive sleep apnea, with over 125,000 patients treated. Revenue comes from selling the Inspire system to hospitals and ambulatory surgery centers primarily in the US through a direct sales force, with select European and Asia-Pacific distribution.

Related stocks: GMED (Globus Medical, Inc.) · ENOV (Enovis Corporation) · TMDX (TransMedics Group, Inc.) · PODD (Insulet Corporation) · SNN (Smith & Nephew SNATS, Inc.)